STOCK TITAN

Nu Skin (NYSE: NUS) adds $175M term loan and $75M revolver

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Nu Skin Enterprises entered into a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term. The term loan was fully drawn at closing and used to repay all amounts outstanding under the prior credit agreement, effectively refinancing the company’s main bank debt.

The revolving facility includes up to $10 million for swingline loans and up to $10 million for letters of credit. Loans bear interest at Term SOFR plus a spread starting at 1.75% or at a base rate plus a spread starting at 0.75%, with both spreads adjustable based on Nu Skin’s consolidated leverage ratio.

The facilities are guaranteed by certain material domestic subsidiaries and secured by liens on the capital stock of material subsidiaries. Key financial covenants require a consolidated leverage ratio not exceeding 2.25 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00, alongside customary restrictions on additional debt, liens, dividends, acquisitions and asset sales.

Positive

  • None.

Negative

  • None.

Insights

Nu Skin refinances bank debt with new secured five-year facilities.

Nu Skin Enterprises has put in place a $175 million term loan and a $75 million revolving credit facility, replacing its prior 2022 credit agreement. The term loan was fully drawn and used to repay all existing borrowings, so this primarily reshapes its bank financing rather than adding new net debt.

Pricing is based on Term SOFR or a base rate plus relatively modest spreads that flex with the company’s consolidated leverage ratio. The agreement is senior secured, guaranteed by material domestic subsidiaries and backed by liens on subsidiaries’ capital stock, which strengthens lenders’ position but increases encumbrance on key assets.

Maintenance covenants include a maximum consolidated leverage ratio of 2.25 to 1.00 and a minimum consolidated interest coverage ratio of 3.00 to 1.00, plus standard limitations on liens, additional indebtedness, dividends and acquisitions. These terms create ongoing discipline around leverage and cash flows; actual flexibility will depend on Nu Skin’s ability to keep leverage and coverage within these thresholds.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
March 27, 2026
 
 
Date of Report (Date of earliest event reported)
 



 
NU SKIN ENTERPRISES, INC.
 
 
(Exact name of registrant as specified in its charter)
 

Delaware
 
001-12421
 
87-0565309
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
 
 
(Address of principal executive offices and zip code)
 

 
(801) 345-1000
 
 
(Registrant’s telephone number, including area code)
 

 
N/A
 
 
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01. Entry into a Material Definitive Agreement.

On March 27, 2026 (the “Closing Date”), Nu Skin Enterprises, Inc. (the “Company”) entered into that certain Second Amendment and Restatement Agreement in connection with the Second Amended and Restated Credit Agreement (the “Credit Agreement”) by and among the Company, as Borrower, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, which amends and restates the Company’s existing amended and restated credit agreement, dated as of June 14, 2022 (as  amended, supplemented or otherwise modified prior to the Closing Date, the “Existing Credit Agreement”). The Credit Agreement provides for a $175 million term loan facility and a $75 million revolving credit facility, each with a term of five years (together, the “Senior Secured Credit Facilities”).  The term loan facility was drawn in full on the Closing Date. The proceeds of the credit facilities are permitted to be used for working capital, capital expenditures and other lawful general corporate purposes of the Company. The Company used all proceeds that were drawn on the Closing Date to repay all amounts outstanding under its Existing Credit Agreement.

The revolving credit facility includes a subfacility for swingline loans of up to $10 million, and up to $10 million of the revolving credit facility is available for the issuance of letters of credit. The term loan facility will amortize in quarterly installments in amounts resulting in an annual amortization of 10.0% per annum, with the remainder payable at final maturity. The loans under the Credit Agreement bear interest, at the option of the Company, either (i) during any interest period selected by the Company, at the Secured Overnight Financing Rate for deposits in U.S. dollars with a maturity comparable to such interest period, adjusted for statutory reserves (“Term SOFR”), plus an initial spread of 1.75% per annum, subject to adjustment based on the consolidated leverage ratio of the Company, or (ii) at the greatest of (x) the federal funds effective rate plus 1/2 of 1%, (y) the prime rate from time to time announced by Bank of America, N.A. and (z) Term SOFR for a one-month interest period plus 1.00%, plus an initial spread of 0.75% per annum, subject to adjustment based on the consolidated leverage ratio of the Company. If an event of default occurs under the Credit Agreement, the interest rate on overdue amounts will increase by 2.00% per annum. The obligations under the Credit Agreement are guaranteed by certain material domestic subsidiaries of the Company (collectively with the Company, the “Loan Parties”) and are secured by a lien on the capital stock of material subsidiaries of the Loan Parties.

The Credit Agreement requires the Company to maintain a consolidated leverage ratio not exceeding 2.25 to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. The Credit Agreement also includes other covenants, including covenants that, subject to certain exceptions, restrict the ability of the Company and its subsidiaries (i) to create, incur, assume or permit to exist any liens, (ii) to incur additional indebtedness, (iii) to make investments and acquisitions, (iv) to enter into mergers, consolidations or similar transactions, (v) to make certain dispositions of assets, (vi) to make dividends, distributions and prepayments of certain indebtedness, (vii) to change the nature of the Company’s business, (viii) to enter into certain transactions with affiliates, (ix) to enter into certain burdensome agreements, (x) to make certain amendments to certain agreements and organizational documents and (xi) to make certain accounting changes.

The Credit Agreement provides for the following events of default: (i) non-payment by any of the Loan Parties of any principal when due or any interest or fees within five Business Days of the due date, (ii) the failure by any Loan Party to comply with any covenant or agreement contained in the Credit Agreement or any other loan document, in certain cases subject to notice and lapse of time, (iii) any representation or warranty pursuant to the Credit Agreement or any other loan document is incorrect in any material respect, (iv) a payment default of the greater of $20 million and 12.5% of Consolidated EBITDA or more under other indebtedness of any Loan Party or any subsidiary of the Company that continues beyond any applicable grace period or any other event or condition under such indebtedness occurs that results in, or permits the holder thereof to cause such indebtedness to become immediately due and payable, (v) certain bankruptcy or insolvency events with respect to any Loan Party or any material subsidiary, (vi) any attachment or similar process issued or levied against any material property and not released within 60 days, (vii) one or more undischarged judgments for the payment of money in an aggregate amount the greater of $20 million and 12.5% of Consolidated EBITDA or more, (viii) certain events relating to ERISA (Employee Retirement Income Security Act) plans that could reasonably be expected to result in a material adverse effect, (ix) the invalidity of any material lien or guarantee granted under the loan documents and (x) the occurrence of a change of control. If an event of default occurs and is continuing, the Administrative Agent may accelerate the amounts and terminate all commitments outstanding under the Credit Agreement and may exercise remedies in respect of the collateral.


From time to time, the Lenders and certain of their affiliates have engaged in, and may in the future engage in, banking and other commercial dealings in the ordinary course of business with the Company. They have received, or may in the future receive, customary fees and commissions for these transactions.

A copy of the Credit Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K. Reference is made to the Credit Agreement for its complete terms. The foregoing description of the Credit Agreement is qualified in its entirety by reference to such exhibit.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Report is incorporated herein by reference into this Item 2.03.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

10.1
Second Amendment and Restatement Agreement in connection with the Second Amended and Restated Credit Agreement among the Company, various financial institutions, and Bank of America, N.A. as administrative agent, dated as of March 27, 2026.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ Chelsea K. Lantz
 
 
Chelsea K. Lantz
 
Chief Financial Officer
   
Date: March 27, 2026
 



FAQ

What new credit facilities did Nu Skin (NUS) enter into on March 27, 2026?

Nu Skin entered a Second Amended and Restated Credit Agreement providing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term, replacing its prior 2022 credit agreement and updating its main bank financing structure.

How will Nu Skin (NUS) use the proceeds from the new term loan?

Nu Skin drew the $175 million term loan in full on the closing date and used all proceeds to repay all amounts outstanding under its existing amended and restated credit agreement, effectively refinancing existing debt rather than funding new investments or acquisitions.

What are the key financial covenants in Nu Skin’s new Credit Agreement?

The Credit Agreement requires Nu Skin to maintain a consolidated leverage ratio not exceeding 2.25 to 1.00 and a consolidated interest coverage ratio of at least 3.00 to 1.00, alongside restrictive covenants on additional debt, liens, dividends, acquisitions, asset sales and certain affiliate transactions.

How are interest rates determined under Nu Skin’s new credit facilities?

Loans bear interest at Nu Skin’s option either at Term SOFR plus an initial 1.75% spread or a base rate plus an initial 0.75% spread. In both cases, the spread is subject to adjustment based on the company’s consolidated leverage ratio, and defaulted amounts accrue an extra 2.00% per annum.

What collateral and guarantees support Nu Skin’s new Credit Agreement?

Obligations under the Credit Agreement are guaranteed by certain material domestic subsidiaries of Nu Skin and secured by liens on the capital stock of material subsidiaries of the loan parties, giving lenders senior secured claims over key subsidiary equity interests in the capital structure.

What events of default could accelerate Nu Skin’s new credit facilities?

Events of default include payment failures, covenant breaches, materially incorrect representations, significant cross-defaults to other debt, certain bankruptcy events, large undischarged judgments, specified ERISA events, invalidation of material liens or guarantees, and a change of control, allowing acceleration and termination of commitments.

Filing Exhibits & Attachments

4 documents
Nu Skin Enter

NYSE:NUS

View NUS Stock Overview

NUS Rankings

NUS Latest News

NUS Latest SEC Filings

NUS Stock Data

349.40M
45.82M
Household & Personal Products
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
PROVO